A partnership between BOC and a Canadian company will see groundbreaking medical technology used to cure cardiovascular disease being made available throughout Europe.
The technology, which uses freezing temperatures to treat diseased tissue of patients with irregular heartbeats, has been developed by Montreal-based CryoCath Technologies, and has been successfully launched in North America.
CryoCath leads the world in cryotherapy products to treat cardiovascular disease. Traditionally, the use of freezing temperatures to treat diseased tissue has been limited by the inability to deliver the treatment in a minimally invasive manner. Cryocath has successfully overcome this obstacle by developing flexible, steerable, minimally invasive catheters to deliver cold therapy safely and effectively.
Having worked closely with BOC Canada, CryoCath turned to BOC Medical in the UK for help in the development of a new nitrous oxide cylinder and valve when it decided to enter the European market.
... to continue reading you must be subscribed
